Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jan 10:2017:bcr2016217313.
doi: 10.1136/bcr-2016-217313.

Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant

Mortimer B O'Connor  1   2 , Neil O'Donovan  3 , Ursula Bond  2 , Mark J Phelan  1   2
Affiliations
Case Reports

Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant

Mortimer B O'Connor et al. BMJ Case Rep. .

Abstract

Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with high-dose steroids. There have been a small number of publications where biological agents have been used to manage refractory cases. To the authors knowledge, there are no publications using biological agents in combination with steroids as a first-line treatment in Takayasu arteritis. In this publication, we document the case of Takayasu arteritis, in a 39-year-old woman, where rituximab was used in combination with steroids as a first-line agent in the setting of poorly controlled bipolar affective disorder.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
A graphical description of laboratory results in combination with medications given during the management of this case.
See this image and copyright information in PMC

References

    1. Watts R, Al-Taiar A, Mooney J et al. . The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 2009;48:1008–11. 10.1093/rheumatology/kep153 - DOI - PubMed
    1. Schmidt J, Kermani TA, Bacani AK et al. . Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 2013;88:822–30. 10.1016/j.mayocp.2013.04.025 - DOI - PubMed
    1. O'Connor MB, O'Donovan N, Phelan MJ et al. . Difficulties in diagnosing Takayasu's arteritis and the benefits of modern day imaging. Ir J Med Sci 2009;178:385–7. 10.1007/s11845-009-0290-z - DOI - PubMed
    1. Proven A, Gabriel SE, Orces C et al. . Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703–8. 10.1002/art.11388 - DOI - PubMed
    1. Hernández-Rodríguez J, García-Martínez A, Casademont J et al. . A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum 2002;47:29–35. 10.1002/art1.10161 - DOI - PubMed

Publication types